Evidence map›Paper›PMID 28835533›Full record

Trial reportSexually transmitted infections2018

A phase II clinical study to assess the feasibility of self and partner anal examinations to detect anal canal abnormalities including anal cancer.

Alan G Nyitray, Joseph T Hicks, Lu-Yu Hwang, Sarah Baraniuk, Margaret White, Stefanos Millas, Nkechi Onwuka, Xiaotao Zhang, Eric L Brown, Michael W Ross and 1 more

Open access · greenAbstract readClinical Trial, Phase II
In one paragraph

Trial report in Sexually transmitted infections, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 2 pooled it
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 50 citations in OpenAlex.

  1. German-Austrian guideline on screening for anal dysplasia and anal carcinoma in people living with HIV.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2025
    Guideline
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Prevention and Screening of HPV Malignancies.Seminars in radiation oncology · 2021
    Review
  15. Article
  16. Article
  17. Article
  18. Do we really need guidelines for HRA during the COVID-19 pandemic?Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland · 2020
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Alan G NyitrayDepartment of Epidemiology, Human Genetics and Environmental Sciences, Center for Infectious Diseases, The University of Texas Health Science Center School of Public Health at Houston, Houston, TX, USA.
Joseph T HicksDepartment of Epidemiology, Human Genetics and Environmental Sciences, Center for Infectious Diseases, The University of Texas Health Science Center School of Public Health at Houston, Houston, TX, USA.
Lu-Yu HwangDepartment of Epidemiology, Human Genetics and Environmental Sciences, Center for Infectious Diseases, The University of Texas Health Science Center School of Public Health at Houston, Houston, TX, USA.
Sarah BaraniukDepartment of Biostatistics, Coordinating Center for Clinical Trials, The University of Texas Health Science Center School of Public Health at Houston, Houston, Texas, USA.
Margaret WhiteGordon Crofoot MD PA, Houston, USA.
Stefanos MillasDepartment of Surgery, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, Texas, USA.
Nkechi OnwukaDepartment of Epidemiology, Human Genetics and Environmental Sciences, The University of Texas Health Science Center School of Public Health at Houston, Houston, Texas, USA.
Xiaotao ZhangDepartment of Epidemiology, Human Genetics and Environmental Sciences, The University of Texas Health Science Center School of Public Health at Houston, Houston, Texas, USA.
Eric L BrownDepartment of Epidemiology, Human Genetics and Environmental Sciences, Center for Infectious Diseases, The University of Texas Health Science Center School of Public Health at Houston, Houston, TX, USA.
Michael W RossUniversity of Minnesota, Program in Human Sexuality, Minneapolis, Minnesota, USA.
Elizabeth Y ChiaoDepartment of Internal Medicine, Baylor College of Medicine, Houston, Texas, USA.
The University of Texas Health Science Center at Houston · USBaylor College of Medicine · USUniversity of Minnesota · US

Funding

The feasibility of self or partner-assisted digital anal exam screeningR21CA181901 · NCI · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI NYITRAY, ALAN GASPAR · 2014 to 2015
$379k
NCI NIH HHS R21 CA181901
6 · The paper itself

Abstract

objectiveAnal cancer is a common cancer among men who have sex with men (MSM); however, there is no standard screening protocol for anal cancer. We conducted a phase II clinical trial to assess the feasibility of teaching MSM to recognise palpable masses in the anal canal which is a common sign of anal cancer in men.

methodsA clinician skilled in performing digital anorectal examinations (DARE) used a pelvic manikin to train 200 MSM, aged 27-78 years, how to do a self-anal examination (SAE) for singles or a partner anal examination (PAE) for couples. The clinician then performed a DARE without immediately disclosing results, after which the man or couple performed an SAE or PAE, respectively. Percentage agreement with the clinician DARE in addition to sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) were calculated for the SAE, PAE and overall.

resultsMen had a median age of 52 years, 42.5% were African American and 60.5% were HIV positive. DARE detected abnormalities in 12 men while the men's SAE/PAEs detected 9 of these. A total of 93.0% of men classified the health of their anal canal correctly (95% CI 89.5 to 96.5). Overall percentage agreement, sensitivity and specificity were 93.0%, 75.0% and 94.2%, respectively, while PPV and NPV were 45.0% and 98.3%, respectively. The six men who detected the abnormality had nodules/masses ≥3 mm in size. More than half of men (60.5%) reported never checking their anus for an abnormality; however, after performing an SAE/PAE, 93.0% said they would repeat it in the future.

conclusionThese results suggest that tumours of ≥3 mm may be detectable by self or partner palpation among MSM and encourage further investigation given literature suggesting a high cure rate for anal cancer tumours ≤10 mm.

Indexed as

Diagnostic Self EvaluationHomosexuality, MaleSexual PartnersAdultAgedAnal CanalAnus NeoplasmsFeasibility StudiesHIV SeropositivityHumansMaleMiddle AgedPatient Education as Topicanal canalanus neoplasmsdigital rectal examinationearly detection of cancerHIVhomosexualitymale

Identifiers

PMID28835533
PMCPMC6173609
OpenAlexW2748086969

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.